Silviya Bradyanova
Overview
Explore the profile of Silviya Bradyanova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
14
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ralchev N, Bradyanova S, Kerekov N, Tchorbanov A, Mihaylova N
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769423
Der p1 is one of the major allergens causing house dust mite (HDM) allergy. Pathological Der p1-specific B cells play a key role in allergic inflammation as producers of allergen-specific...
2.
Design, Development and Immunogenicity Study of a Multi-Epitope Vaccine Prototype Against SARS-CoV-2
Atanasova M, Dimitrov I, Ralchev N, Markovski A, Manoylov I, Bradyanova S, et al.
Pharmaceuticals (Basel)
. 2024 Nov;
17(11).
PMID: 39598409
SARS-CoV-2 caused the COVID-19 pandemic, which overwhelmed global healthcare systems. Over 776 million COVID-19 cases and more than 7 million deaths were reported by WHO in September 2024. COVID-19 vaccination...
3.
Stoyanova E, Mihaylova N, Ralchev N, Bradyanova S, Manoylov I, Raynova Y, et al.
Mar Drugs
. 2024 Oct;
22(10).
PMID: 39452870
Melanoma is one of the most common tumors worldwide, and new approaches and antitumor drugs for therapy are being investigated. Among the promising biomolecules of natural origin for antitumor research...
4.
Stoyanova E, Mihaylova N, Ralchev N, Bradyanova S, Manoylov I, Raynova Y, et al.
Mar Drugs
. 2024 May;
22(5).
PMID: 38786612
Materials And Methods: We established a murine model of melanoma by challenging C57BL/6 mice with a B16F10 cell line for solid tumor formation in experimental animals. The anticancer properties of...
5.
Delimitreva S, Boneva G, Chakarova I, Hadzhinesheva V, Zhivkova R, Markova M, et al.
Immunol Res
. 2024 May;
72(4):811-827.
PMID: 38771487
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the activation of the immune response against self antigens. Numerous reproductive complications, including reduced birth rate and complications for the...
6.
Bradyanova S, Manoylov I, Boneva G, Kechidzhieva L, Tchorbanov A, Nikolova-Ganeva K
Immunology
. 2024 Mar;
172(2):269-278.
PMID: 38430118
The aetiology and progression of systemic lupus erythematosus (SLE) resulted from a complex sequence of events generated both from genetic and epigenetic processes. In the current research, the effect of...
7.
Nikolova-Ganeva K, Bradyanova S, Manoylov I, Boneva G, Tchorbanov A
Immunobiology
. 2022 Oct;
227(6):152282.
PMID: 36183628
Genetic susceptibility is necessary but not sufficient for systemic lupus erythematosus (SLE) to appear indicating that environmental factors are also key components in the disease onset. Aberrant DNA methylation profile...
8.
Stoyanova E, Mihaylova N, Ralchev N, Ganova P, Bradyanova S, Manoylov I, et al.
Mar Drugs
. 2022 Jun;
20(6).
PMID: 35736195
Finding new effective compounds of natural origin for composing anti-tumor vaccines is one of the main goals of antitumor research. Promising anti-cancer agents are the gastropodan hemocyanins-multimeric copper-containing glycoproteins used...
9.
Mihaylova N, Bradyanova S, Chipinski P, Chausheva S, Kyurkchiev D, Tchorbanov A
Scand J Immunol
. 2020 Jun;
92(3):e12915.
PMID: 32533866
Systemic lupus erythematosus is an autoimmune syndrome characterized by the development of autoantibodies to a wide range of antigens. Together with B cells, respective self-reactive T cells have an important...
10.
Stoyanova E, Mihaylova N, Manoylov I, Bradyanova S, Raynova Y, Idakieva K, et al.
Int Immunopharmacol
. 2020 May;
84:106566.
PMID: 32416451
Various natural compounds have been tested as anticancer therapeutics in clinical trials. Most promising direction for antitumor therapy is the use of substances which enhance the immune system response stimulating...